Comparative Pharmacology
Head-to-head clinical analysis: INSULIN versus NOVOLIN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INSULIN versus NOVOLIN N.
Insulin vs NOVOLIN N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lowers blood glucose by binding to insulin receptors on target cells, activating tyrosine kinase activity, promoting glucose uptake via GLUT4 translocation, stimulating glycogen synthesis, and inhibiting gluconeogenesis and lipolysis.
Insulin analog that lowers blood glucose by promoting cellular uptake of glucose, inhibiting hepatic glucose production, and stimulating lipogenesis and protein synthesis.
Individualized based on weight, insulin sensitivity, and metabolic needs. Type 1 diabetes: total daily dose (TDD) 0.3–1.5 units/kg/day, typically 50% basal (long-acting) and 50% prandial (rapid/short-acting). Type 2 diabetes: starting dose 0.1–0.2 units/kg/day or 10 units basal once daily, titrated based on fasting glucose. Intensive regimens use basal-bolus approach.
Subcutaneous injection. Typical starting dose for type 1 diabetes: 0.5-1.0 units/kg/day divided into 2 doses (morning and evening). For type 2 diabetes: 10 units once or twice daily, adjusted based on blood glucose levels.
None Documented
None Documented
Terminal elimination half-life: 5-6 minutes for regular insulin; biphasic with initial rapid phase (4-5 min) and slower phase. Clinical context: short half-life necessitates continuous infusion or multiple daily injections.
10-12 hours for intermediate-acting insulin, with a peak effect at 2-8 hours and duration up to 24 hours. Terminal half-life in subcutaneous depot is 4-6 hours.
Renal: ~60-80% (degraded in kidney); hepatic: ~20-40% (degraded in liver); only a small fraction (<1%) excreted unchanged in urine.
Renal: 30-80% of dose excreted as unchanged insulin and metabolites. Biliary/fecal: negligible (<1%).
Category A/B
Category C
Insulin
Insulin